Earlier this year, Prasad said he wanted to see more stringent reviews, writing on X that “The FDA did nothing to speed gene therapy, other than talk about how they will use uncontrolled endpoints. But we want to speed effective gene therapy, not ineffective gene therapy. The FDA had no solution for that.”. IMU does have controlled endpoints with clinical trials done on cancer patients who have failed multiple lines of current SoC treatment.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $330.0K | 24.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 65 | 11878041 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 4119067 | 12 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |